Boulle Therapeutics is a long-term investor in novel techniques for treating harmful diseases.
Mission and Vision
Boulle Therapeutics identifies, invests in, and supports the development of early, seed stage innovations that have the potential to save lives and improve the quality of life for large numbers of people.
TRAINED THERAPEUTIX DISCOVERY – TTXD
Our team is using advanced bioengineering to treat the most detrimental of human diseases by taking control of the innate immune response. We have been successful in using new nanobiologic therapeutics to regulate the body’s natural “trained immunity”.
We are at the forefront of advanced research to address some of the most recalcitrant and debilitating diseases, including cancer and serious infection.
Our proprietary technology is based on a decade of development in therapeutics that induce an immune response, for example, against tumors or to dampen hyperinflammation following organ transplantation.
Nanobiologics are materials constructed from molecular building blocks that our body produces naturally. The therapeutics ‘hijack’ natural mechanisms using materials that are inherently well tolerated by the body.
Our proprietary technology is founded upon the scientific and biomedical engineering work by investigators from the Icahn School of Medicine at Mount Sinai in New York and the Radboud University Medical Center in The Netherlands.
Jean Boulle Medtech is the anchor founding investor in NanoPhagix LLC, which is developing a patented nanoparticle drug treatment for atherosclerosis. The drug is designed to directly target rupture-prone plaques inside the vessel walls of the human circulatory system to reduce vessel inflammation. That should in turn reduce the narrowing of the vessel and the risk of plaque cap rupture, either or both of which events can result in blood clots, heart attack, stroke or other organ damage. The drug is currently undergoing animal trials.
Copyright © 2019 Jean Boulle Group. All rights reserved.